News

Medical Dialogues25m
AstraZeneca Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...
CURE9h
CAR T-Cell Therapy Leads to Remission in Retired Air Force Pilot With Lymphoma
Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of ...
AstraZeneca (LSE:AZN) Gains FDA Approval For Datroway In Treating Advanced Lung Cancer
AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...
Business Weekly17h
AstraZeneca steers another potential blockbuster drug
Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
Correction to AstraZeneca Datroway Article on June 24
The lung-cancer drug Datroway, being jointly developed by AstraZeneca and Daiichi Sankyo, has been approved in the U.S. to treat adult patients with non-small cell lung cancer. "AstraZeneca's Datroway ...